Skip to content

R&D at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$27.1M-1.5%
NeoGenomics logo
NeoGenomicsNEO
$10.76M+19.3%
Illumina logo
IlluminaILMN
$252M+2.0%
CareDx logo
CareDxCDNA
$21.42M+15.6%
Veracyte logo
VeracyteVCYT
$27.1M+52.9%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$23.62M-2.4%

Other financials

Income statement

See full
Revenue$696.6M+38.8%
Operating income-$93.5M-18.1%
Net income-$85.1M-27.1%
EPS (diluted)-$0.60-20.0%

Balance sheet

See full
Cash & equivalents$1.1B+11.7%
Total debt$240.1M+22.7%
Total equity$1.8B+43.1%
Total assets$2.6B+50.9%

Cash flow

See full
Operating cash flow$40.2M-9.6%
CapEx$22.1M+1.5%
Free cash flow$18.0M-20.3%

Valuation

See full
Market cap$36.12B+94.7%
Enterprise value$35.27B+98.8%
P/S14.4×+5.0×

Profitability

See full
Gross margin42.9%
Operating margin-13%+0.6pp
Net margin-14.6%+0.6pp
FCF margin4.2%-0.5pp

Returns & leverage

See full
Return on equity-29%+4.1pp
Debt / equity0.1×0.0×
Current ratio-0.9×

Where this comes from

Reported directly by Natera, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Natera, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Natera, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Natera, Inc.'s R&D?
Natera, Inc. (NTRA) reported R&D of $210.7M in Q1 2026.
How has Natera, Inc.'s R&D changed year-over-year?
Natera, Inc.'s R&D increased by 63.2% year-over-year, from $129.08M to $210.7M.
What is the long-term trend for Natera, Inc.'s R&D?
Over 4 years (2021 to 2025), Natera, Inc.'s R&D has grown at a 24.0% compound annual growth rate (CAGR), from $264.21M to $624.11M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.